```json
{
"ranked_hypotheses": [
{
"rank": 1,
"id": "H7",
"title": "TYROBP-Dependent CR3 (ITGAM/CD11B) Signaling Drives Synaptic Pruning While TREM2 Provides Compensatory Neuroprotective Signals",
"primary_target": "ITGAM (CR3/CD11b), Complement pathway (C1q, C3)",
"composite_score": 4.30,
"dimension_scores": {
"mechanistic_plausibility": 0.70,
"evidence_strength": 0.65,
"novelty": 0.55,
"feasibility": 0.45,
"therapeutic_potential": 0.60,
"druggability": 0.55,
"safety_profile": 0.30,
"competitive_landscape": 0.50,
"data_availability": 0.60,
"reproducibility": 0.40
},
"evidence_for": [
{"claim": "CR3 mediates complement-dependent synaptic pruning by microglia", "pmid": "22509280"},
{"claim": "TREM2 deficiency reduces complement gene expression in microglia", "pmid": "29395366"},
{"claim": "C1q and C3 deposition on synapses correlates with early AD synaptic loss", "pmid": "27078027"},
{"claim": "Pegcetacoplan (C3 inhibitor) is FDA-approved for related indication (geographic atrophy)", "pmid": "Approved drug"},
{"claim": "Complement inhibition blocks synaptic loss in mouse models", "pmid": "27078027"}
],
"evidence_against": [
{"claim": "C3/C5 inhibitors have poor BBB penetration - eculizumab requires ~2400mg/week IV with negligible CNS concentrations", "pmid": "Approved drug label"},
{"claim": "Long-term complement inhibition causes meningococcal infection risk - contraindicated in elderly", "pmid": "Approved drug label"},
{"claim": "Synaptic pruning is essential for normal brain function - insufficient pruning causes epilepsy/autism in complement-deficient mice", "pmid": "Complement KO studies"},
{"claim": "Peripheral complement inhibition doesn't significantly reduce brain complement activity", "pmid": "Clinical pharmacology studies"}
],
"key_insight": "Most tractable hypothesis from drug development perspective - FDA-approved complement inhibitors exist and can serve as proof-of-concept tools. CNS penetration is the critical barrier but is a solvable engineering problem (Denali BBB platform, engineered antibodies).",
"recommended_experiments": [
"CNS-penetrant C1s inhibitor in 5xFAD mice (proximal to CR3)",
"Test whether complement inhibition phenocopies TYROBP KO for synaptic protection",
"Assess whether complement inhibition impairs normal hippocampal synaptic plasticity"
],
"therapeutic_confidence": 0.45
},
{
"rank": 2,
"id": "H2",
"title": "TYROBP Signals Through Distinct Downstream Pathways for Inflammatory vs. Phagocytic Functions — Only Inflammatory Arm Requires TYROBP",
"primary_target": "SYK, TYROBP ITAM domain",
"composite_score": 4.00,
"dimension_scores": {
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.55,
"novelty": 0.65,
"feasibility": 0.40,
"therapeutic_potential": 0.55,
"druggability": 0.50,
"safety_profile": 0.25,
"competitive_landscape": 0.40,
"data_availability": 0.55,
"reproducibility": 0.55
},
"evidence_for": [
{"claim": "TREM2 engages both SYK-dependent and SYK-independent signaling cascades", "pmid": "29758444"},
{"claim": "NF-κB activation by TREM2 requires ITAM signaling", "pmid": "29758444"},
{"claim": "Fostamatinib (SYK inhibitor) is FDA-approved with demonstrated CNS activity in stroke (R406)", "pmid": "26682775"},
{"claim": "TREM2 contains distinct functional domains that can be selectively targeted", "pmid": "27840056"},
{"claim": "TREM2-DAP10 heterodimers signal through PI3K/Akt independent of SYK", "pmid": "16709931"}
],
"evidence_against": [
{"claim": "TREM2 KO impairs phagocytosis - contradicts SYK-independent phagocytosis model", "pmid": "26675736"},
{"claim": "SYK inhibitors block phagocytosis globally in immune cells", "pmid": "20592283"},
{"claim": "SYK inhibitors cause cytopenias, immunosuppression - unacceptable safety profile for chronic AD prevention", "pmid": "Approved drug label"},
{"claim": "No selective TYROBP ITAM inhibitor exists - current SYK inhibitors block all SYK signaling including DAP10 pathways", "pmid": "Research gap"},
{"claim": "ITAM-independent TREM2 signaling is not well-characterized - molecular identity and functional significance remain speculative", "pmid": "29758444"}
],
"key_insight": "High target tractability (SYK is druggable, FDA-approved drugs exist) but lacks selectivity. The bifurcation model is mechanistically plausible but unsupported. Requires development of ITAM-selective inhibitors.",
"recommended_experiments": [
"Compare TYROBP ITAM-mutated knock-in vs. complete KO in 5xFAD mice",
"Test whether SYK inhibition in TYROBP KO microglia further impairs phagocytosis",
"Measure pSYK, pAKT, pNF-κB in TYROBP KO microglia following TREM2 agonism"
],
"therapeutic_confidence": 0.35
},
{
"rank": 3,
"id": "H1",
"title": "CD33-TYROBP Axis Drives Neurotoxicity While TREM2 Uses TYROBP-Independent Pathways for Homeostatic Function",
"primary_target": "CD33 (SIGLEC-3), TYROBP",
"composite_score": 3.95,
"dimension_scores": {
"mechanistic_plausibility": 0.55,
"evidence_strength": 0.60,
"novelty": 0.50,
"feasibility": 0.40,
"therapeutic_potential": 0.55,
"druggability": 0.45,
"safety_profile": 0.30,
"competitive_landscape": 0.30,
"data_availability": 0.55,
"reproducibility": 0.45
},
"evidence_for": [
{"claim": "CD33 risk alleles increase CD33 expression and suppress microglial amyloid clearance", "pmid": "23882164"},
{"claim": "CD33 is a robust AD GWAS hit - genetic validation exists", "pmid": "GWAS studies"},
{"claim": "Gemtuzumab ozogamicin (anti-CD33 ADC) is FDA-approved for AML - validated target class", "pmid": "Approved drug"},
{"claim": "TREM2 can form heterodimers with DAP10, signaling through PI3K/Akt without TYROBP", "pmid": "16709931"},
{"claim": "CD33 contains ITIM domains that inhibit phagocytosis when engaged", "pmid": "23882164"}
],
"evidence_against": [
{"claim": "TREM2 knockout in 5xFAD mice worsens amyloid pathology - contradicts preserved homeostatic function", "pmid": "26675736"},
{"claim": "TREM2 R47H/+ heterozygous humans show substantially increased AD risk - reducing TREM2-TYROBP arm is not protective", "pmid": "23300972"},
{"claim": "TYROBP KO mice show reduced microglial survival and proliferation - contradicts TREM2 compensation", "pmid": "29395366"},
{"claim": "CD33 structure inconsistency - CD33 has only two Ig domains and poorly characterized signaling", "pmid": "SIGLEC biology"},
{"claim": "CD33 ITIM signaling is not proven to be TYROBP-dependent in the same manner as TREM2", "pmid": "23882164"},
{"claim": "Anti-CD33 antibodies have poor BBB penetration - gemtuzumab relies on bone marrow access", "pmid": "Approved drug pharmacology"}
],
"key_insight": "Targets the right axis (CD33-TYROBP inhibition) with genetic validation, but the compensatory mechanism is not supported. BBB penetration is the critical barrier. Partial validation through CD33 KO studies, but TREM2 KO data contradicts compensation model.",
"recommended_experiments": [
"Generate TYROBP/CD33 double KO in 5xFAD mice - if CD33-TYROBP is primary axis, double KO should not differ from TYROBP KO alone",
"Single-cell RNA-seq of TYROBP KO vs. TREM2 KO microglia - should diverge if TREM2 retains TYROBP-independent function",
"Test whether anti-CD33 antibodies achieve sufficient brain exposure with BBB-penetrant delivery platforms"
],
"therapeutic_confidence": 0.25
},
{
"rank": 4,
"id": "H5",
"title": "Stage-Dependent Role of TYROBP — Early Blockade is Neuroprotective by Preventing Harmful Microglial Activation While Late Blockade Impairs Beneficial Plaque Clearance",
"primary_target": "TYROBP, TREM2, disease stage biomarkers",
"composite_score": 3.85,
"dimension_scores": {
"mechanistic_plausibility": 0.50,
"evidence_strength": 0.50,
"novelty": 0.60,
"feasibility": 0.30,
"therapeutic_potential": 0.55,
"druggability": 0.25,
"safety_profile": 0.25,
"competitive_landscape": 0.40,
"data_availability": 0.45,
"reproducibility": 0.45
},
"evidence_for": [
{"claim": "TREM2 R47H variant shows stage-dependent effects - protective early, detrimental late", "pmid": "30792888"},
{"claim": "DAM signature appears early in AD progression", "pmid": "28394883"},
{"claim": "TREM2-dependent microglia accumulate at amyloid plaques and are essential for containment", "pmid": "27477018"},
{"claim": "TREM2 KO shows opposite phenotypes at different disease stages in some models", "pmid": "Multiple studies"},
{"claim": "Biomarkers (pTau181, NfL) exist to stage AD and potentially guide intervention timing", "pmid": "Clinical biomarkers"}
],
"evidence_against": [
{"claim": "Nasu-Hakola disease (TYROBP LOF in humans) manifests in 3rd-4th decade - still early relative to AD - demonstrating devastating consequences", "pmid": "11774071"},
{"claim": "TREM2 R47H is a ligand-binding defect (partial loss), not equivalent to TYROBP deletion which removes both TREM2 and CD33 signaling", "pmid": "30792888"},
{"claim": "Germline deletion triggers developmental compensation not recapitulated by adult-onset inhibition", "pmid": "Developmental biology"},
{"claim": "No TYROBP-targeting pharmacological agents exist to test timing hypothesis", "pmid": "Research gap"},
{"claim": "Intervention window timing is undefined - no biomarkers distinguish TYROBP-dependent from independent phases", "pmid": "Research gap"},
{"claim": "Even transient TYROBP inhibition may deplete microglial populations if TYROBP is essential for survival", "pmid": "29395366"}
],
"key_insight": "Conceptually elegant - timing hypothesis is supported by TREM2 R47H data - but fundamentally constrained by Nasu-Hakola disease. Requires developmental compensation model to be wrong and identification of intervention timing biomarkers.",
"recommended_experiments": [
"Inducible TYROBP deletion in adult 5xFAD mice (tamoxifen at 6 months) - definitive test of developmental compensation",
"Dose-response study with partial TYROBP reduction (50-70%) to determine if partial inhibition is safer than complete loss",
"Biomarker studies to define TYROBP activity phase in human AD progression"
],
"therapeutic_confidence": 0.30
},
{
"rank": 5,
"id": "H6",
"title": "TYROBP Exerts Opposite Effects in Resident Microglia vs. Infiltrating Peripheral Macrophages — Neuroprotection Requires Peripheral Cell-Specific Targeting",
"primary_target": "TYROBP, CCR2, ITGAM (CD11b)",
"composite_score": 3.55,
"dimension_scores": {
"mechanistic_plausibility": 0.55,
"evidence_strength": 0.45,
"novelty": 0.65,
"feasibility": 0.25,
"therapeutic_potential": 0.50,
"druggability": 0.20,
"safety_profile": 0.35,
"competitive_landscape": 0.30,
"data_availability": 0.35,
"reproducibility": 0.40
},
"evidence_for": [
{"claim": "Peripheral monocyte recruitment into CNS contributes to neuroinflammation in AD", "pmid": "17785825"},
{"claim": "TYROBP associates with CR3 (CD11b/CD18), which mediates peripheral myeloid cell adhesion and transmigration", "pmid": "Integrin biology"},
{"claim": "Microglia and peripheral macrophages adopt distinct transcriptional programs in AD", "pmid": "20668246"},
{"claim": "DAP12/TYROBP expression differs between resident microglia and infiltrating monocytes", "pmid": "Mouse Brain Atlas"},
{"claim": "CCR2 antagonists (cenicriviroc) exist and are in clinical trials for related conditions", "pmid": "Phase III trials"}
],
"evidence_against": [
{"claim": "Bone marrow transplantation studies contradict model - TYROBP deletion in donor cells leads to worse outcomes, not better", "pmid": "17785825"},
{"claim": "TREM2 deletion in bone marrow cells impairs their recruitment to plaques and worsens pathology - same would occur with TYROBP deletion", "pmid": "17785825"},
{"claim": "Peripheral cell-specific TYROBP targeting technology does not exist", "pmid": "Research gap"},
{"claim": "Resident microglia do not compensate through TYROBP-independent pathways - TREM2 KO studies show they don't", "pmid": "26675736"},
{"claim": "Achieving peripheral TYROBP inhibition while sparing microglia requires cell-type selective delivery not currently possible", "pmid": "Drug delivery technology"},
{"claim": "CX3CR1-deficient mice (impaired peripheral monocyte recruitment) do not show neuroprotective phenotype", "pmid": "CX3CR1 KO studies"}
],
"key_insight": "Elegant hypothesis addressing the cell-type specificity problem, but contradicted by bone marrow transplantation studies and undermined by absence of cell-type selective delivery technology.",
"recommended_experiments": [
"Parabiosis experiments to distinguish resident vs. peripheral cell contributions to TYROBP KO phenotype",
"Develop cell-type selective delivery platforms (Fc-engineering, targeted nanoparticles)",
"Test whether CCR2 antagonists phenocopy peripheral TYROBP deletion"
],
"therapeutic_confidence": 0.20
},
{
"rank": 6,
"id": "H4",
"title": "CLEC7A (Dectin-1) Compensates for TREM2 Function via Alternative DAP12 Homologs in TYROBP-Deficient Microglia",
"primary_target": "CLEC7A, FcRγ (FCER1G), SYK",
"composite_score": 3.50,
"dimension_scores": {
"mechanistic_plausibility": 0.45,
"evidence_strength": 0.40,
"novelty": 0.55,
"feasibility": 0.25,
"therapeutic_potential": 0.40,
"druggability": 0.15,
"safety_profile": 0.30,
"competitive_landscape": 0.15,
"data_availability": 0.40,
"reproducibility": 0.45
},
"evidence_for": [
{"claim": "CLEC7A signals through both DAP12 and FcRγ chains", "pmid": "25605924"},
{"claim": "Dectin-1/FcRγ heterodimers maintain SYK activation independent of TYROBP", "pmid": "20592283"},
{"claim": "CLEC7A deficiency worsens amyloid pathology", "pmid": "31878459"},
{"claim": "Microglia express multiple DAP12-family adapters with overlapping functions", "pmid": "Human Protein Atlas"},
{"claim": "CLEC7A is protective in neurodegeneration context", "pmid": "31878459"}
],
"evidence_against": [
{"claim": "CLEC7A requires ITAM-bearing adaptors (FcRγ or DAP12) - cannot signal if all ITAM adapters are lost", "pmid": "25605924"},
{"claim": "TREM2 KO mice show worsened pathology - CLEC7A compensation is insufficient in vivo", "pmid": "26675736"},
{"claim": "CLEC7A ligand (β-glucan) is not enriched in AD brain - no physiological activator in neurodegeneration", "pmid": "Dectin biology"},
{"claim": "No pharmacological tool exists to selectively enhance CLEC7A-FcRγ signaling", "pmid": "Research gap"},
{"claim": "Microglial expression of FcRγ and coupling to CLEC7A in brain has not been demonstrated", "pmid": "Research gap"},
{"claim": "CLEC7A deficiency worsening pathology doesn't prove it compensates for TREM2 loss - only that it's independently needed", "pmid": "31878459"}
],
"key_insight": "Weakest hypothesis from drug development perspective - no chemical matter exists, mechanism is speculative, and contradicted by TREM2 KO data. Best viewed as mechanistic explanation for compensatory pathways rather than therapeutic strategy.",
"recommended_experiments": [
"CRISPR deletion of FcRγ (FCER1G) in TYROBP KO microglia - if CLEC7A-FcRγ is critical, deletion should eliminate neuroprotection",
"RNA-seq of TYROBP KO vs. WT microglia for FcRγ and DAP10 expression",
"CLEC7A KO × TYROBP KO double KO to test whether CLEC7A is the compensatory pathway"
],
"therapeutic_confidence": 0.15
},
{
"rank": 7,
"id": "H3",
"title": "TYROBP Regulates Microglial Epigenetic State Transitions — Its Loss Locks Microglia in a Neuroprotective Pre-Disease State",
"primary_target": "NFATC1, HDAC1, TREM2/TYROBP complex",
"composite_score": 3.40,
"dimension_scores": {
"mechanistic_plausibility": 0.40,
"evidence_strength": 0.45,
"novelty": 0.60,
"feasibility": 0.30,
"therapeutic_potential": 0.45,
"druggability": 0.35,
"safety_profile": 0.20,
"competitive_landscape": 0.25,
"data_availability": 0.40,
"reproducibility": 0.30
},
"evidence_for": [
{"claim": "TREM2 activation induces NFAT nuclear translocation and calcium signaling", "pmid": "25730876"},
{"claim": "Epigenetic landscape defines microglial activation states - environment modulates chromatin accessibility", "pmid": "29107332"},
{"claim": "Disease-associated microglia (DAM) represent a distinct epigenetic state", "pmid": "28394883"},
{"claim": "NFAT signaling recruits chromatin remodeling complexes in immune cells", "pmid": "Roadmap Epigenomics"},
{"claim": "Cyclosporine A and tacrolimus (NFAT inhibitors) are FDA-approved with good CNS penetration", "pmid": "Approved drugs"}
],
"evidence_against": [
{"claim": "Acute TREM2 blockade reverses DAM signature within days - state is ligand-dependent, not epigenetically self-sustaining", "pmid": "28076333"},
{"claim": "NFAT translocation is rapid and transient - cannot explain chronic epigenetic remodeling over days to weeks", "pmid": "25730876"},
{"claim": "NFAT is one of many DAM-driving TFs - DAM signature is controlled by AP-1, NF-κB, PU.1, and others", "pmid": "28394883"},
{"claim": "HDAC inhibitors affect all HDAC-dependent transcriptional programs - no selective microglial HDAC inhibitor exists", "pmid": "HDAC inhibitor pharmacology"},
{"claim": "HDAC inhibitors have failed in neurodegenerative disease trials (creatin for Huntington's)", "pmid": "NCT02139886"},
{"claim": "Calcineurin inhibitors (CsA, FK506) are profound immunosuppressants with nephrotoxicity - contraindicated for chronic AD", "pmid": "Approved drug labels"}
],
"key_insight": "Fundamentally undermined by reversibility of DAM signatures. If NFAT-driven epigenetics controlled the DAM state, removing TREM2 would not reverse within days. Mechanism requires sustained chromatin modifications, but TREM2 effects are rapid and transient.",
"recommended_experiments": [
"ATAC-seq comparison of TYROBP KO vs. WT vs. TREM2 KO microglia - determine if TYROBP KO has unique chromatin landscape",
"Acute NFAT inhibition in 5xFAD mice - should not phenocopy TYROBP deletion if hypothesis is correct",
"Time-course ATAC-seq after TREM2 agonism in TYROBP KO cells"
],
"therapeutic_confidence": 0.15
}
],
"knowledge_edges": [
{
"source": "TYROBP",
"edge_type": "encodes",
"target": "DAP12",
"weight": 1.0,
"context": "TYROBP is the gene encoding DAP12 adapter protein"
},
{
"source": "TREM2",
"edge_type": "signals_through",
"target": "TYROBP",
"weight": 0.95,
"context": "TREM2 requires TYROBP for ITAM-mediated downstream signaling"
},
{
"source": "TREM2",
"edge_type": "signals_through",
"target": "DAP10",
"weight": 0.70,
"context": "TREM2 can form heterodimers with DAP10 for PI3K/Akt signaling"
},
{
"source": "CD33",
"edge_type": "inhibits",
"target": "microglial_phagocytosis",
"weight": 0.75,
"context": "CD33 ITIM signaling suppresses amyloid clearance"
},
{
"source": "CD33",
"edge_type": "associates_with",
"target": "TYROBP",
"weight": 0.60,
"context": "CD33 can recruit TYROBP but signaling mechanism poorly characterized"
},
{
"source": "ITGAM (CR3)",
"edge_type": "mediates",
"target": "synaptic_pruning",
"weight": 0.85,
"context": "CR3 mediates complement-dependent synaptic elimination"
},
{
"source": "CR3",
"edge_type": "requires",
"target": "TYROBP",
"weight": 0.80,
"context": "CR3 signaling downstream of complement activation requires TYROBP"
},
{
"source": "C1QA",
"edge_type": "deposits_on",
"target": "synapses",
"weight": 0.75,
"context": "C1q deposition initiates complement cascade on synapses"
},
{
"source": "C3",
"edge_type": "mediates",
"target": "synaptic_loss",
"weight": 0.80,
"context": "C3 activation is required for complement-dependent synaptic pruning"
},
{
"source": "CLEC7A",
"edge_type": "signals_through",
"target": "FcRγ",
"weight": 0.75,
"context": "CLEC7A can signal through FcRγ as alternative to TYROBP"
},
{
"source": "SYK",
"edge_type": "activated_by",
"target": "TYROBP_ITAM",
"weight": 0.90,
"context": "SYK is activated by ITAM phosphorylation on TYROBP"
},
{
"source": "SYK",
"edge_type": "bifurcates_to",
"target": "NFkB_pathway",
"weight": 0.70,
"context": "SYK activation leads to NF-κB-mediated inflammatory cytokine production"
},
{
"source": "NFATC1",
"edge_type": "regulated_by",
"target": "TYROBP",
"weight": 0.65,
"context": "TYROBP-mediated calcium signaling activates NFAT transcription factors"
},
{
"source": "TREM2_R47H",
"edge_type": "impairs",
"target": "ligand_binding",
"weight": 0.85,
"context": "R47H variant reduces but does not eliminate TREM2 function"
},
{
"source": "TYROBP_LOF",
"edge_type": "causes",
"target": "Nasu-Hakola_disease",
"weight": 1.0,
"context": "Complete TYROBP loss-of-function causes early-onset neurodegeneration"
},
{
"source": "DAM_signature",
"edge_type": "induced_by",
"target": "TREM2",
"weight": 0.80,
"context": "TREM2 activation drives transition to disease-associated microglia state"
},
{
"source": "DAM_signature",
"edge_type": "reversed_by",
"target": "acute_blockade",
"weight": 0.85,
"context": "DAM signature reverses within days of TREM2 blockade - state is not epigenetically locked"
},
{
"source": "CCR2",
"edge_type": "mediates",
"target": "monocyte_infiltration",
"weight": 0.75,
"context": "CCR2 guides peripheral monocyte recruitment into CNS"
},
{
"source": "peripheral_macrophages",
"edge_type": "distinct_from",
"target": "resident_microglia",
"weight": 0.85,
"context": "Microglia and peripheral macrophages adopt distinct transcriptional programs"
},
{
"source": "HDAC1",
"edge_type": "modulates",
"target": "microglial_epigenetic_state",
"weight": 0.60,
"context": "HDAC activity influences microglial activation state chromatin accessibility"
}
],
"synthesis_summary": {
"paradox_resolution": "The TYROBP deficiency paradox cannot be resolved without addressing Nasu-Hakola disease - TYROBP LOF in humans causes early-onset neurodegeneration, directly contradicting the premise that its inhibition would be therapeutic in AD. The most likely resolution is developmental compensation: germline TYROBP deletion triggers compensatory pathways (DAP10 upregulation, alternative adapter expression) during development that are not recapitulated by adult-onset pharmacological inhibition. This explains why TYROBP KO mice show neuroprotection in acute amyloid models while humans with TYROBP LOF develop progressive neurodegeneration.",
"top3_recommendations": [
{
"rank": 1,
"hypothesis_id": "H7",
"rationale": "Most tractable therapeutic approach - CR3/complement inhibition blocks synaptic pruning downstream of TYROBP without affecting microglial survival signaling. FDA-approved complement inhibitors exist as proof-of-concept tools. Critical development need is CNS-penetrant formulation (Denali BBB platform, engineered antibodies). Estimated 5-7 year development timeline.",
"key_experiment": "CNS-penetrant C1s inhibitor in 5xFAD mice"
},
{
"rank": 2,
"hypothesis_id": "H2",
"rationale": "Highest target tractability - SYK inhibitors are FDA-approved and show CNS activity (R406 stroke data). Bifurcated signaling model is mechanistically plausible. Critical development need is ITAM-selective inhibition (current SYK inhibitors lack selectivity). Alternative path is DAP10 agonist development to enhance compensatory pathway.",
"key_experiment": "TYROBP ITAM-mutated knock-in vs. complete KO comparison"
},
{
"rank": 3,
"hypothesis_id": "H1",
"rationale": "Targets the right biological axis - CD33 inhibition achieves partial phenocopy of TYROBP deletion (removes CD33-mediated phagocytosis suppression while preserving TREM2). Genetic validation is strong (CD33 GWAS hits). Critical barrier is BBB penetration - requires BBB-penetrant antibody engineering.",
"key_experiment": "CD33/TYROBP double KO to test axis specificity"
}
],
"critical_knowledge_gaps": [
"Whether developmental compensation explains the discrepancy between TYROBP KO mouse neuroprotection and Nasu-Hakola disease",
"Whether partial TYROBP reduction (50-70%) is therapeutic without causing Nasu-Hakola-like pathology",
"Whether CNS-penetrant complement inhibitors can achieve sufficient brain exposure to block synaptic pruning",
"Whether TREM2-DAP10 heterodimers can be pharmacologically enhanced without engaging TYROBP ITAM signaling",
"Whether the intervention timing window for TYROBP inhibition can be identified using existing biomarkers"
],
"strategic_recommendation": "Do not pursue TYROBP as a direct target. The therapeutic index is likely narrow to nonexistent given Nasu-Hakola disease. Instead, pursue downstream targets that preserve the beneficial effects of TREM2 signaling while inhibiting pathogenic pathways: (1) CNS-penetrant complement inhibitors for Hypothesis 7, (2) DAP10-selective agonists for TREM2 survival pathway enhancement, (3) CD33 antagonists with BBB-penetrant delivery for Hypothesis 1. TREM2 agonists (AL002 in Phase II) represent the most advanced and validated approach in this space.",
"competitive_landscape_summary": "TREM2 agonists dominate the field (Alector/AbbVie AL002 in Phase II, >$500M partnership). Complement inhibitors are emerging (Apellis moving into CNS). SYK inhibitors exist but have no AD program. TYROBP-specific programs do not exist - represents either an opportunity or a risk depending on hypothesis validity. BBB penetration technology (Denali